RABNIL-LS
Description
- Combines Rabeprazole 20 mg (enteric-coated) for acid suppression and Levosulpiride 75 mg (SR) for improved gut motility.
- Effective in treating GERD, dyspepsia, bloating, nausea, and non-ulcer dyspepsia.
- Levosulpiride enhances gastric emptying and acts as an antiemetic.
- Rabeprazole provides long-lasting relief by inhibiting proton pumps in the stomach lining.
- Once-daily oral dosing ensures better patient compliance.
- Suitable for chronic and recurrent gastric disorders under medical supervision.
Composition
RABEPRAZOLE-20 MG (PEIIETS), LEVOSULPIDE-75 MG
Benefits
RABNIL-LS provides dual-action therapy by addressing both acid suppression and motility regulation. It is especially effective in treating chronic gastritis, acid reflux, and indigestion that doesn't respond to standard acid-reducing agents alone. Rabeprazole offers rapid and long-lasting acid control, while Levosulpiride improves gastric emptying, reduces nausea, and alleviates discomfort caused by bloating and delayed digestion. The combination improves overall quality of life in patients with GERD, functional dyspepsia, and other upper gastrointestinal disorders.
Introduction
RABNIL-LS is a fixed-dose combination of Rabeprazole 20 mg and Levosulpiride 75 mg, formulated for effective management of gastroesophageal reflux disease (GERD), acid reflux, functional dyspepsia, and other acid-related disorders. Rabeprazole, a proton pump inhibitor (PPI), reduces stomach acid production by blocking the H+/K+ ATPase enzyme system, while Levosulpiride, a prokinetic agent, enhances gastrointestinal motility and relieves bloating and nausea. Together, they offer comprehensive relief from upper GI symptoms caused by excessive acid secretion and poor gut motility.
